Filter Results:
(793)
Show Results For
- All HBS Web
(1,552)
- People (1)
- News (333)
- Research (793)
- Multimedia (8)
- Faculty Publications (574)
Show Results For
- All HBS Web
(1,552)
- People (1)
- News (333)
- Research (793)
- Multimedia (8)
- Faculty Publications (574)
Sort by
- Article
Invisible Monuments and the Costs of Pharmaceutical Regulation: Twenty-Five Years of Drug Lag Debate
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "Invisible Monuments and the Costs of Pharmaceutical Regulation: Twenty-Five Years of Drug Lag Debate." Pharmacy in History 45, no. 1 (2003): 3–17.
- 23 Jul 2013
- First Look
First Look: July 23
fortnight if unexecuted. Bank finance and trade credit had tided Getit through tough times in the past, and Getit still had a Rs 250 million bank line to draw on. Should he take the venture capital investment? And if so, what implications... View Details
Keywords: Anna Secino
- 2018
- Chapter
The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century
By: Nicholas Bagley, Benjamin Berger, Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
On the 35th anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormous changes in the markets for therapies for rare diseases that have emerged over recent decades. The most prominent example is the fact that the profit-maximizing price of new... View Details
Keywords: Health Care and Treatment; Laws and Statutes; Research and Development; Investment; Markets; Monopoly
Bagley, Nicholas, Benjamin Berger, Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern. "The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century." Chap. 4 in Innovation Policy and the Economy, Volume 19, edited by Josh Lerner and Scott Stern, 97–137. University of Chicago Press, 2018.
- February 2011 (Revised June 2011)
- Case
Hardina Smythe and the Healthcare Investment Conundrum
By: Matthew Rhodes-Kropf, Ann Leamon and Lisa Strope
Hardina Smythe, a recent MBA graduate, has just joined a top-tier venture capital firm in the difficult environment of late 2010. Her first assignment is to evaluate three different deals and make recommendations to the partners. Each potential investment has strengths... View Details
Keywords: Venture Capital; Asset Management; Private Equity; Entrepreneurship; Investment; Health Care and Treatment; Innovation and Invention; Financial Services Industry
Rhodes-Kropf, Matthew, Ann Leamon, and Lisa Strope. "Hardina Smythe and the Healthcare Investment Conundrum." Harvard Business School Case 811-073, February 2011. (Revised June 2011.)
- 22 Mar 2016
- First Look
March 22, 2016
investors have a positive impact on the growth, performance, and survival of firms as well as their follow-on fundraising. The positive impact of angel financing is independent of the level of venture activity and entrepreneur... View Details
Keywords: Sean Silverthorne
- July 2000 (Revised November 2001)
- Case
Catalyst Medical Solutions
By: Amy C. Edmondson, Richard M.J. Bohmer and Naomi Atkins
Faced with a drop in the NASDAQ, four eHealth entrepreneurs must decide between two distribution strategies for their new company's technology. The team, comprised of three full-time resident physicians and an MBA, has developed software to enable electronic... View Details
Keywords: Product Development; Health Care and Treatment; Distribution; Strategy; Venture Capital; Applications and Software; Partners and Partnerships; Borrowing and Debt; Information Technology Industry; Service Industry
Edmondson, Amy C., Richard M.J. Bohmer, and Naomi Atkins. "Catalyst Medical Solutions." Harvard Business School Case 601-014, July 2000. (Revised November 2001.)
- 13 May 2014
- Op-Ed
The Alibaba Effect
ago. It has done more for China's small- and medium-sized enterprises than any government policy, ministry, or bank. Alibaba's only limits are those imposed by the speed at which these enterprises continue to grow. Health and welfare... View Details
- 22 Aug 2005
- Research & Ideas
Balancing the Future Against Today’s Needs
Urquhart, GE Commercial Finance Stanford Graduate School of Business professor Charles A. O'Reilly III and Harvard Business School professor Michael L. Tushman outline one approach in their Harvard Business Review article, "The... View Details
Keywords: by Paul Michelman
- 03 Dec 2008
- What Do You Think?
Can Housing and Credit be “Nudged” Back to Health?
refinancing. These recommendations fall at the intersection of financial and social engineering. They raise the question of whether housing and credit can be "nudged" back to health in this manner or whether there is some better... View Details
Keywords: by Jim Heskett
- February 2021
- Supplement
HNA Group: Global Excellence with Chinese Characteristics (C)
By: William C. Kirby, Billy Chan and John P. McHugh
July 2017 was supposed to be a triumphant month for HNA Group. The latest Fortune Global 500 list showed the company had again skyrocketed in its ranking to no. 170, an improvement of over 200 positions from the year prior. Yet earlier that same July, the mysterious... View Details
Keywords: Conglomerate; Airline Industry; Coronavirus; Financial Risk; Debt; Bankruptcy; Global Strategy; Restructuring; Health Pandemics; Financial Markets; Organizational Change and Adaptation; Financial Condition; Globalized Firms and Management; Business and Government Relations; Air Transportation Industry; Financial Services Industry; China
Kirby, William C., Billy Chan, and John P. McHugh. "HNA Group: Global Excellence with Chinese Characteristics (C)." Harvard Business School Supplement 321-123, February 2021.
- 29 May 2018
- First Look
New Research and Ideas, May 29, 2018
from digital platforms have the potential to improve our understanding of gentrification and enable new measures of how neighborhoods change in close to real time. Combining data on businesses from Yelp with data on gentrification from the Census, Federal Housing View Details
Keywords: Dina Gerdeman
- August 2012 (Revised August 2024)
- Case
ABC Pharmaceuticals
By: Regina E. Herzlinger and Erik R. Sparks
This case asks students to price a new drug that is in Stage II of its clinical trials. It contains detailed estimates of the time required and costs for all the steps needed to commercialize a drug in the U.S. Students will learn virtually all the steps required to... View Details
Keywords: Drug Development; Price; Product; Product Launch; Health Industry; Health Industry; Health Industry
Herzlinger, Regina E., and Erik R. Sparks. "ABC Pharmaceuticals." Harvard Business School Case 313-041, August 2012. (Revised August 2024.)
- January 2009
- Teaching Note
Biocon: Launching a New Cancer Drug in India (TN)
By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details
- December 2004 (Revised April 2006)
- Case
Nestle and Alcon--The Value of a Listing
By: Mihir A. Desai, Vincent Dessain and Anders Sjoman
In response to a perceived undervaluation by the capital markets, Nestle is considering divesting a part of its ophthalmology subsidiary, Alcon, and must decide on a listing location. In the process, students are challenged to wrestle with the valuation of a... View Details
Keywords: Business Conglomerates; International Finance; Corporate Entrepreneurship; Markets; Taxation; Business Subsidiaries; Valuation; Health Industry; Health Industry; Europe; United States
Desai, Mihir A., Vincent Dessain, and Anders Sjoman. "Nestle and Alcon--The Value of a Listing." Harvard Business School Case 205-056, December 2004. (Revised April 2006.)
- December 2012 (Revised November 2014)
- Case
W.R. Grace & Co.: Dealing with Asbestos Torts
By: Stuart C. Gilson and Sarah L. Abbott
A manufacturer of building products and specialty chemicals, W. R. Grace & Co. filed for Chapter 11 bankruptcy in 2001 in response to a flood of lawsuits alleging that its products contained asbestos, and had caused hundreds of thousands of people to contract... View Details
Keywords: Bankruptcy Reorganization; Business Failures; Environmental Regulations; Class Action Lawsuits; Natural Environment; Valuation; Health Disorders; Capital Structure; Restructuring; Lawsuits and Litigation; Chemicals; Crisis Management; Insolvency and Bankruptcy; Legal Liability; Construction Industry; Chemical Industry; United States
Gilson, Stuart C., and Sarah L. Abbott. "W.R. Grace & Co.: Dealing with Asbestos Torts." Harvard Business School Case 213-046, December 2012. (Revised November 2014.)
- 13 Apr 2020
- Research & Ideas
Small Businesses Are Worse Off Than We Thought
in-person operations, sinking demand to near zero. Professional services businesses have fared better, but they have not been spared—just 63 percent say they could weather a four-month public health lockdown. [div class=infogram-embed... View Details
- December 2010
- Teaching Note
Roche's Acquisition of Genentech (TN)
By: Bo Becker and Carliss Y. Baldwin
Teaching Note for 210-040. View Details
- 29 Mar 2016
- First Look
March 29, 2016
https://www.hbs.edu/faculty/Pages/item.aspx?num=50648 2016 New York: Oxford University Press Consumers, Corporations, and Public Health: A Case-Based Approach to Sustainable Business By: Quelch, John A. Abstract—The public health footprint... View Details
Keywords: Sean Silverthorne
- October 2019 (Revised April 2020)
- Background Note
Note on Funding Deep Tech Startups
By: Karim Lakhani, Peter Barrett and Noubar Afeyan
This Background Note provides essential information on funding deep technologies—those technologies that were inherently capital intensive, time consuming, risky, and potentially disruptive. Both dilutive and non-dilutive sources of investment are highlighted, along... View Details
Keywords: Entrepreneurship; Energy; Venture Capital; Corporate Finance; Initial Public Offering; Investment; Health Testing and Trials; Innovation and Invention; Technological Innovation; Intellectual Property; Product Design; Product Development; Information Technology; Research and Development; Risk and Uncertainty; Technology Industry; Biotechnology Industry; United States; North America; Europe; Asia
Lakhani, Karim, Peter Barrett, and Noubar Afeyan. "Note on Funding Deep Tech Startups." Harvard Business School Background Note 620-029, October 2019. (Revised April 2020.)
- November 2021
- Article
Determining Variable Costs in the Acute Urolithiasis Cycle of Care Through Time-driven Activity-based Costing
By: Tyler R. McClintock, David F. Friedlander, Aiden Y. Feng, Mahek A. Shah, Daniel J. Pallin, Steven L. Chang, Angela M. Bader, Thomas W. Feeley, Robert S. Kaplan and George E. Haleblian
Objective. To characterize full cycle of care costs for managing an acute ureteral stone using time-driven activity-based costing.
Methods. We defined all phases of care for patients presenting with an acute ureteral stone and built an... View Details
Methods. We defined all phases of care for patients presenting with an acute ureteral stone and built an... View Details
Keywords: Time-Driven Activity-Based Costing; Health Care and Treatment; Cost; Activity Based Costing and Management
McClintock, Tyler R., David F. Friedlander, Aiden Y. Feng, Mahek A. Shah, Daniel J. Pallin, Steven L. Chang, Angela M. Bader, Thomas W. Feeley, Robert S. Kaplan, and George E. Haleblian. "Determining Variable Costs in the Acute Urolithiasis Cycle of Care Through Time-driven Activity-based Costing." Urology 157 (November 2021): 107–113.